Whitnell & Co. cut its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 13,831 shares of the biopharmaceutical company’s stock after selling 1,416 shares during the quarter. Whitnell & Co.’s holdings in Bristol-Myers Squibb were worth $701,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of BMY. Cornerstone Wealth Group LLC grew its holdings in shares of Bristol-Myers Squibb by 49.5% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 60,522 shares of the biopharmaceutical company’s stock worth $3,069,000 after acquiring an additional 20,030 shares during the last quarter. Principle Wealth Partners LLC acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth $239,000. Sector Gamma AS grew its holdings in shares of Bristol-Myers Squibb by 2.6% in the 3rd quarter. Sector Gamma AS now owns 1,386,722 shares of the biopharmaceutical company’s stock worth $70,321,000 after acquiring an additional 35,000 shares during the last quarter. Rikoon Group LLC grew its holdings in shares of Bristol-Myers Squibb by 0.9% in the 3rd quarter. Rikoon Group LLC now owns 45,638 shares of the biopharmaceutical company’s stock worth $2,314,000 after acquiring an additional 400 shares during the last quarter. Finally, Lavaca Capital LLC acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth $283,000. Institutional investors own 80.40% of the company’s stock.
BMY has been the topic of a number of recent research reports. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. Peel Hunt reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, October 29th. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. UBS Group raised their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $56.64.
In related news, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now directly owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.
Shares of Bristol-Myers Squibb stock traded up $0.44 during midday trading on Friday, hitting $58.02. The company’s stock had a trading volume of 11,418,626 shares, compared to its average volume of 12,766,524. The firm has a market capitalization of $91.88 billion, a P/E ratio of 14.58, a PEG ratio of 1.31 and a beta of 0.71. The stock has a 50-day simple moving average of $52.90 and a 200-day simple moving average of $48.19. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $58.46.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.11. The firm had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.09 earnings per share. As a group, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 2.83%. Bristol-Myers Squibb’s payout ratio is 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Portfolio Manager
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.